Amyris

California
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Caution
Medium Risk

Summary:

Amyris, does not provide viewpoint protections for its employees but has not publicly terminated business relationships based on views or beliefs. The company supports ESG within its business practices. Amyris covers transgender-related medical costs for its employees and their children. The company supports BLM and the Equality Act. Amyris frequently uses its reputation to promote LGBTQ causes and is committed to carbon neutrality by 2050. The company co-signed a letter to law firms demanding an improvement in diversity in order to retain business with the company. For these reasons, Amyris receives a Medium Risk rating.

View Full Report
Generate Reports
Clear
Toast